Skip to main content
OpenTrials
Completed

NCT Number: NCT01360866

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Research Site, Gatineau, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and Female outpatients 18-65 years of age

Eligible subjects from Trials 331-10-227, 331-10-228 or 331-12-282:

  • Subjects who completed participation in the Double-blind Randomization Phase (i.e. Week 14 visit) in Trial 331-10-227, Trial 331-10-228, or Trial 331-12-282 or
  • Subjects who met criteria for a response, but did not meet criteria for remission at Week 14 of either trial

Eligible subjects from other Phase 3, Double-blind, Brexpiprazole MDD trials:

  • Subjects who completed the last scheduled visit of the prior Double-blind Randomized Phase 3 trial.

Exclusion criteria

  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving OPC-34712.
  • Subjects with a major protocol violation during the course of their participation in the Double-blind Randomization Phase

Treatment and study plan

OPC-34712

Drug

Tablet

Escitalopram

Drug

Tablet

Other names: Lexapro

Fluoxetine

Drug

Capsule

Other names: Prozac

Paroxetine CR

Drug

Controlled-release tablets

Other names: Paxil CR

Sertraline

Drug

Tablets

Other names: Zoloft

Duloxetine

Drug

Delayed-release capsules

Other names: Cymbalta

venlafaxine XR

Drug

Extended-release capsules

Other names: Effexor XR

Primary outcomes

  1. Adverse Events (AEs) - All Participants

    Time frame: From screening to week 52/early termination

    To assess the frequency and severity of AEs as the variables of safety and tolerability of brexpiprazole.

Secondary outcomes

  1. Mean Change From Baseline in Clinical Global Impression - Severity (CGI-S) of Illness Score

    Time frame: From screening to week 52/early termination

    The severity of illness for each participant was rated using the CGI-S . On the basis of the investigator answer to the question: "Considering your total clinical experience with this particular population, how mentally ill was the participant at that time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

  2. Change From Baseline in Mean Clinical Global Impression - Improvement (CGI-I) Score

    Time frame: From screening to week 52/early termination

    The efficacy of trial treatment was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. All responses were compared to the participant's condition at screening. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse and 7 = very much worse.

  3. Summary of Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score

    Time frame: From screening to week 52/early termination

    The SDS was a self-rated instrument used to measure the effect of the participant's symptoms on regular life responsibilities. The SDS was a visual analogue scale that used spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the 3 domains with scores from 0 = not at all, to 10 = extremely.

    Scores of 5 and above were associated with significant functional impairment.

  4. Change From Baseline in the Inventory of Depressive Symptomatology - Self Report (IDS-SR) Total Score

    Time frame: From screening to week 52/early termination

    The IDS-SR was a 30-item self-report measure used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of MDD. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. The IDS-SR Total Score is the sum of ratings of 28 item scores. The possible IDS-SR Total Score ranges from 0 (best) to 84 (worst).

    Under item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items are not included in the calculation of the total score. Item 11 or item 12 should be completed but not both, and similarly, item 13 or item 14 should be completed but not both. If the number of items recorded is at least 23 and at most 27, the IDS-SR Total Score will be the mean of the recorded items multiplied by 28 and then rounded to the first decimal place.

Sponsors and collaborators

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Industry

Registry information

Official study title

A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial

Acronym: Orion

Important dates

Study start
2011
Primary completion
2017
Study completion
2017
First posted
May 26, 2011
Registry last updated
Sep 17, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.